npj Precision Oncology · 2017 · 100 citations · 67 references
MedicineCancer BiologyOncologyCancer PharmacologyMolecular OncologyOncogenesCancer GenomicsCancer ProgressionLung Cancer PharmacotherapyOncogenic Signaling PathwaysTargeted Cancer TherapyTherapeutic ResistanceKinase Inhibitor ResistanceOncogenic Signaling NetworksProtein Kinase InhibitorsRational PolytherapyResistance To Targeted TherapyResistance To Tyrosine Kinase InhibitorsTargeted Resistance MechanismsTherapeutic Resistance Mechanisms
The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong the lives of individuals with cancer. Inevitably, however, the treated tumors recur as resistance to these targeted therapies develops. Here, we review the major mechanisms by which a cancer cell can evade targeted therapy, focusing on mechanisms of resistance to kinase inhibitors in lung cancer. We discuss the promising concept of rational upfront polytherapy in lung cancer, which involves concurrently targeting multiple proteins in critical signaling pathways in a cancer cell to prevent or delay resistance.
67
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine · 2005 · 3.9K citations · Full text
Medicine, Oncology, Pharmacology +15